A new variant of COVID-19 virus is showing up, and is especially prevalent in the North Eastern region of the US. The variant known as XBB.1.5 has emerged as the dominant strain in that area, according to the Centers for Disease Control and Prevention, making up nearly half of new infections. The XBB.1.5 variant made up three quarters of new COVID-19 cases in Connecticut, Rhode Island, Maine, Massachusetts, New Hampshire, and Vermont in the final week of 2022. In New York and New Jersey, the rate was only a few percentage points lower
Adding to the general population’s vulnerability is the somewhat lower effectiveness of the inoculation booster, and the very low uptake of the booster. Barely fifteen percent of people eligible to get the new bivalent COVID booster shot that targets the omicron variant have requested it, according to that CDC website.
The expectation now is that when children return to school after the winter holiday break, there will be a sharp upturn in infections both in the school population and in the general population as the virus gets a new stream of carriers.
Rather than getting infected yourself and relying on the diminished capability of hospitals and staff to treat you, keeping safe and uninfected is the sensible alternative.
This makes use of Enovid, one of the simplest and most effective barriers against COVID-19, RSV and the flu, a must-have for anyone who is vulnerable. This goes equally for anyone who is moving in and out of environments where other people could already be infected and spreading the viruses around unknowingly.
Enovid nitric oxide spray is a proven barrier to viral infection through the upper airways. Suppose you are traveling on a crowded bus or train, sharing an elevator, or working in a closed room with others. In that case, the possibility that you could be infected by someone else increases dramatically. Enovid blocks the ability of air-borne viruses to find a lodging place and infect your nasal passages. Free-ranging viruses are the primary vector of both COVID-19 and the flu.
NONS (nitric oxide nasal spray) blocks the infectiousness of air-borne viruses by halting viral replication at the point of entry in the upper nasal cavity. This will rapidly reduce the total viral load, killing up to 99% of the viruses within two minutes. It can prevent transmission and lower the severity of infection. Think of Enovid as a hand sanitizer equivalent for your nose.
Nitric oxide creates a chemical barrier with antiviral and antimicrobial qualities. It forms a physical barrier in the nasal passages to stop viruses and microbes from finding a surface to penetrate. Nitric oxide doesn’t just block the viruses but actually kills them. This is achieved because nitric oxide interferes with mRNA transcription and replication of both viral ribonucleotide and viral RNA synthesis. This is the same effect achieved by the Pfizer and Moderna vaccines distributed for inoculation against COVID-19.
Is the bivalent booster effective against omicron variants of COVID-19?
The new form of the inoculation is known as bivalent booster. According to the US FDA website, COVID-19 vaccines include a component of the original virus strain to provide broad protection against COVID-19 and a component of the omicron variant to provide better protection against COVID-19 caused by the omicron variant. These are called bivalent COVID-19 vaccines because they contain these two components. A bivalent COVID-19 vaccine may also be referred to as “updated” COVID-19 vaccine booster dose.
The original data from the first vaccines didn’t test for protection against infection, but was focusing on symptomatic disease, and they protected well against that. It’s still too early to know exactly how the bivalent booster will work in the longer term. So far, the main effect of the bivalent booster compared to the regular inoculation against COVID-19 has been to reduce hospitalization rates rather than rates of infection.